Scientists discover novel B cell that tempers autoimmunity
Infusions of purified IL-27 regulatory B cells (I27-Bregs) reduced symptoms in mouse models of multiple sclerosis and autoimmune uveitis.
List view / Grid view
Infusions of purified IL-27 regulatory B cells (I27-Bregs) reduced symptoms in mouse models of multiple sclerosis and autoimmune uveitis.
The new nanoparticle adjuvant improved antibody production following vaccination against HIV, diphtheria and influenza in mouse models.
Scientists used a new screen to identify FAM72A as a cause of mutagenesis that affects antibody development in COVID-19 and cancer.
Researchers discover a new precision strategy to hinder the infection of the coronavirus, leading to the filing of a new drug patent.
Biologics solutions from discovery to manufacturing.
Neutralising monoclonal antibodies protected aged macaque monkeys from SARS-CoV-2 and reduced inflammation, including in cerebrospinal fluid, a new study has shown.
This whitepaper overviews phenotypic and functional characterisation of CAR-T cells with advanced flow cytometry and live-cell analysis.
Scientists have developed a novel technique for the targeted clearance of senescent cells to improve treatments for ageing and other conditions.
Researchers have used genetically engineered SARS-CoV-2 Spike proteins to boost antibodies against a range of coronaviruses in mice.
Save time by measuring 48 immune factors, generating more than 1,800 data points from a single plate, with a small sample volume.
Laboratories operating under GMP or GLP regulations must follow guidelines set by agencies to protect scientific integrity or demonstrate quality assurance of manufactured products.
Scientists at the New York University (NYU) Abu Dhabi have used nuclear magnetic resonance (NMR) techniques to determine the structure of a specific nanobody, Nb23. Drug Target Review’s Victoria Rees spoke with lead researcher Professor Gennaro Esposito to find out how their findings could lead to a better understanding of…
Despite the rapid deployment of vaccines among global populations, therapeutics such as antibodies are still required. Here, Dr Steve Carroll, Vice President of Pre-clinical Sciences at IGM Biosciences, explains how a potential Immunoglobulin M (IgM) antibody treatment has been developed that shows promise for combatting SARS-CoV-2 and variants of concern in pre‑clinical…
This ebook has features on the development of intranasally-delivered antibodies to combat SARS-CoV-2 and how the structure of a nanobody was determined using nuclear magnetic resonance methods.
A new study has identified a key protein on the surface of the hepatitis C virus that interacts with a receptor found on human cells.